Skip to content
Inciteful Med
Resources About us Ask a Question

What is Sjögren's Syndrome: Causes and Types Explained

Published: | Updated:

Sjögren's syndrome is a systemic autoimmune disease where the body attacks its tear and salivary glands, causing severe dryness, fatigue, and joint pain. It primarily affects middle-aged women. Primary Sjögren's is standalone, while secondary occurs with other diseases like Rheumatoid Arthritis.

Key Takeaways

  • • Sjögren's syndrome is an autoimmune disease that attacks moisture-producing glands, leading to severe dry eyes and dry mouth.
  • • The condition is systemic and frequently causes profound fatigue, joint pain, and brain fog in addition to dryness.
  • • Women are 9 to 20 times more likely to develop the condition than men, with diagnosis typically occurring in middle adulthood.
  • • Anti-SSA and anti-SSB antibodies are key diagnostic markers that correlate with a more widespread, active disease.
  • • Primary Sjögren's is a standalone condition, while secondary Sjögren's occurs alongside other autoimmune diseases like lupus or rheumatoid arthritis.

Sjögren’s syndrome is a chronic, systemic autoimmune condition where the body’s immune system mistakenly attacks its own moisture-producing glands, primarily the tear (lacrimal) and saliva (salivary) glands [1][2]. While this leads to the hallmark symptoms of severe dry eyes and dry mouth, it is not merely a “dryness” disease [1]. Because it affects the whole body, it frequently causes profound, debilitating fatigue and joint pain [3]. It predominantly affects women and usually appears in middle adulthood [4][5]. Biologically, the disease is driven by immune cells that invade and damage these glands, often accompanied by specific blood markers called anti-SSA and anti-SSB antibodies [6][7]. Doctors categorize the condition into two types: “Primary” when it occurs on its own as a standalone systemic disease, and “Secondary” when it develops alongside another established autoimmune disease, such as Rheumatoid Arthritis or Lupus [1][8].

Who Gets Sjögren’s Syndrome?

Sjögren’s syndrome is considered a relatively rare but deeply impactful disease. Estimates show it affects between 2 to 10 out of every 10,000 people (about 0.02% to 0.1% of the population) [9][10]. About 3.5 to 7 new cases are diagnosed per 100,000 people each year [11][12].

When looking at the demographics of who is most affected, several clear patterns emerge:

  • Gender: Sjögren’s is overwhelmingly diagnosed in females. Women are 9 to 20 times more likely to develop the condition than men [13][4].
  • Age: The disease is most commonly diagnosed in middle-aged adults, though “late-onset” cases can appear between ages 50 and 70 [5][14]. It is very rare in children, though when it does occur in pediatric patients, it can involve more severe systemic features [15][16].
  • Ethnicity and Geography: Where a person lives and their ethnic background can influence how often the disease occurs and how it presents. For instance, some studies indicate higher incidence rates in non-Latina Asian and non-Latina white women compared to Latina or non-Latina Black women [12][13].

What is Happening Inside Your Body?

At its core, Sjögren’s syndrome is an exocrinopathy—a disease of the glands that secrete fluids outward [17]. The biological mechanisms behind it involve a complex misdirection of the immune system.

The Role of Lymphocytes

In a healthy body, white blood cells called lymphocytes (specifically B cells and T cells) protect against infections. In Sjögren’s syndrome, these cells become dysregulated and physically invade the salivary and tear glands [6][17]. This invasion creates chronic inflammation and damages the glandular tissue, severely reducing its ability to produce moisture [1][18].

More Than Just Innocent Bystanders

The cells that line the glands, known as epithelial cells, aren’t just passive tissue being attacked by the immune system. Research shows they actively participate in the disease process [19]. They secrete chemical signals (cytokines and chemokines) that recruit even more immune cells to the area, fueling a continuous loop of chronic inflammation [20][21].

Anti-SSA (Ro) and Anti-SSB (La) Antibodies

Autoantibodies are proteins produced by the immune system that mistakenly target the body’s own tissues. In Sjögren’s syndrome, anti-SSA (Ro) and anti-SSB (La) antibodies are clinical hallmarks of the disease [3][22].

  • Markers of Disease, Not the Primary Cause: Interestingly, the physical damage to the glands is mostly caused by the infiltrating lymphocytes, not by the antibodies themselves [1][23].
  • Why They Matter: Even though they don’t directly destroy the glands, these antibodies are highly specific diagnostic markers [7][24]. Their presence strongly correlates with a more active systemic disease and a higher risk of symptoms outside the glands—known as extraglandular manifestations [3][25]. These can include profound joint pain, persistent brain fog, nerve numbness (neuropathy), or inflammation in the lungs.

Primary vs. Secondary Sjögren’s: What is the Distinction?

While the severe dry eyes, dry mouth, and fatigue might feel identical to a patient, doctors distinguish between two clinical presentations of the disease.

Primary Sjögren’s Syndrome (pSS)

This diagnosis is given when the condition exists as a standalone, distinct chronic autoimmune disorder [1][8].

  • It is a systemic disease on its own, meaning it can affect the whole body, not just the glands.
  • Understanding Your Risks: Patients with primary Sjögren’s require careful monitoring because the disease is associated with higher risks of other issues, including thyroid disorders, cardiovascular disease, and a specific type of cancer called B-cell non-Hodgkin lymphoma [26][17]. While hearing the word “lymphoma” can be scary, it is important to know that the absolute risk remains very low for most patients. Your rheumatologist will monitor you closely for this during routine checkups, often by feeling for swollen lymph nodes and running regular blood work [27].

Secondary Sjögren’s Syndrome

This diagnosis is used when Sjögren’s symptoms occur in a patient who already has another well-established autoimmune condition [1][28].

  • Common Associated Conditions: It most frequently appears alongside Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), scleroderma, or myositis [8][29].
  • Clinical Nuance: There are some underlying physiological differences between the two. For instance, the pattern of inflammation in the salivary glands of someone with secondary Sjögren’s alongside RA can look microscopically different than in someone with primary Sjögren’s [30].

A Note on Terminology: Because primary Sjögren’s often eventually overlaps with other autoimmune diseases, the medical community is gradually shifting away from the “primary” and “secondary” labels. Many experts now prefer the umbrella term “Sjögren’s disease” (SjD) to emphasize that it is always a serious, systemic condition regardless of what other diseases a patient may have [31].

What Comes Next?

Understanding what Sjögren’s is and how it functions is only the first step. Because it is a systemic disease, management requires a team approach. You will likely work closely with a rheumatologist to manage widespread inflammation and fatigue, an ophthalmologist for your eye health, and a dentist specializing in dry mouth care to protect your teeth. Treatment focuses on relieving symptoms, preventing organ damage, and improving your daily quality of life.

Frequently Asked Questions

What is the difference between primary and secondary Sjögren's syndrome?
Primary Sjögren's occurs as a standalone autoimmune condition. Secondary Sjögren's develops in someone who already has another well-established autoimmune disease, such as rheumatoid arthritis or lupus.
What do anti-SSA and anti-SSB antibodies mean for Sjögren's?
These antibodies are clinical markers that help doctors diagnose Sjögren's syndrome. Their presence often indicates a more active systemic disease and a higher risk of symptoms outside the moisture glands, like joint pain or brain fog.
Who is most likely to get Sjögren's syndrome?
Sjögren's syndrome predominantly affects women, who are 9 to 20 times more likely to develop the condition than men. It is most commonly diagnosed in middle-aged adults, typically between the ages of 50 and 70.
What complications should I watch for with primary Sjögren's?
Because it is a systemic disease, primary Sjögren's carries a higher risk of other issues, including thyroid disorders, cardiovascular disease, and a specific type of cancer called B-cell non-Hodgkin lymphoma. Your doctor will monitor you closely for these during routine checkups.

Questions for Your Doctor

  • • Do my blood tests show anti-SSA or anti-SSB antibodies, and how does that affect my long-term monitoring plan?
  • • Based on my symptoms and lab work, do I have primary Sjögren's, or is there evidence of an underlying autoimmune disease like Rheumatoid Arthritis or Lupus?
  • • Given my specific risk factors, what signs of complications (such as swollen lymph nodes or lung issues) should we be watching for?
  • • How frequently will you need to run blood work or perform physical exams to monitor my systemic risks?
  • • Which specific specialists (such as a rheumatologist, ophthalmologist, or dentist) should I add to my care team to manage my daily symptoms?

Questions for You

  • • Have any blood relatives been diagnosed with Sjögren's, Rheumatoid Arthritis, Lupus, or other autoimmune conditions?
  • • Besides dry eyes and dry mouth, have I noticed other symptoms like joint pain, profound fatigue, persistent rashes, or brain fog?
  • • How much are my symptoms impacting my daily quality of life, such as my ability to eat, sleep, work, or speak?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Renal Disease in Primary Sjögren's Syndrome.

    Aiyegbusi O, McGregor L, McGeoch L, et al.

    Rheumatology and therapy 2021; (8(1)):63-80 doi:10.1007/s40744-020-00264-x.

    PMID: 33367966
  2. 2

    Sjögren's syndrome.

    André F, Böckle BC

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2022; (20(7)):980-1002 doi:10.1111/ddg.14823.

    PMID: 35775593
  3. 3

    Autoantibodies, detection methods and panels for diagnosis of Sjögren's syndrome.

    Shen L, Suresh L

    Clinical immunology (Orlando, Fla.) 2017; (182()):24-29 doi:10.1016/j.clim.2017.03.017.

    PMID: 28390965
  4. 4

    [Sjögren's Syndrome: Epidemiological, Diagnostic, Therapeutic and Evolutionary Aspects in the Aristide-Le-Dantec Teaching Hospital of Dakar, Senegal (2012-2016)].

    Salissou GM, Moustapha N, Kaba C, et al.

    Bulletin de la Societe de pathologie exotique (1990) 2020; (113(3)):136-142 doi:10.3166/bspe-2020-0124.

    PMID: 33825393
  5. 5

    [Late-onset sjögren's syndrom].

    Koszarny A, Górak A, Majdan M

    Wiadomosci lekarskie (Warsaw, Poland : 1960) 2019; (72(9 cz 1)):1687-1690.

    PMID: 31586984
  6. 6

    B cell dysregulation in primary Sjögren's syndrome: A review.

    Ibrahem HM

    The Japanese dental science review 2019; (55(1)):139-144 doi:10.1016/j.jdsr.2019.09.006.

    PMID: 31687053
  7. 7

    Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy.

    Parisis D, Chivasso C, Perret J, et al.

    Journal of clinical medicine 2020; (9(7)) doi:10.3390/jcm9072299.

    PMID: 32698400
  8. 8

    Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome) focusing on autoimmune rheumatic diseases.

    Alani H, Henty JR, Thompson NL, et al.

    Scandinavian journal of rheumatology 2018; (47(2)):141-154 doi:10.1080/03009742.2017.1324909.

    PMID: 28927315
  9. 9

    Prevalence of Primary Sjögren's Syndrome in a US Population-Based Cohort.

    Maciel G, Crowson CS, Matteson EL, Cornec D

    Arthritis care & research 2017; (69(10)):1612-1616 doi:10.1002/acr.23173.

    PMID: 27998024
  10. 10

    [Epidemiology and manifestations of Sjögren's disease].

    Aringer M, Tausche AK

    Zeitschrift fur Rheumatologie 2026; doi:10.1007/s00393-026-01796-3.

    PMID: 41790166
  11. 11

    New-onset seizure In Peripartum period: a case of Sjögren's syndrome with renal artery stenosis.

    Parajuli R, Basyal S, Dahal A, Pradhan R

    Oxford medical case reports 2025; (2025(9)):omaf199 doi:10.1093/omcr/omaf199.

    PMID: 40979806
  12. 12

    The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County.

    Izmirly PM, Buyon JP, Wan I, et al.

    Arthritis care & research 2019; (71(7)):949-960 doi:10.1002/acr.23707.

    PMID: 30044541
  13. 13

    Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.

    Brito-Zerón P, Acar-Denizli N, Zeher M, et al.

    Annals of the rheumatic diseases 2017; (76(6)):1042-1050 doi:10.1136/annrheumdis-2016-209952.

    PMID: 27899373
  14. 14

    Elderly-onset primary Sjögren's syndrome focused on clinical and salivary gland ultrasonographic features.

    Lee KA, Choi W, Kim J, et al.

    Joint bone spine 2021; (88(4)):105132 doi:10.1016/j.jbspin.2021.105132.

    PMID: 33486109
  15. 15

    Sjögren's syndrome in children: about 15 cases in Guinea Conakry.

    Condé K, Guelngar CO, Barry MC, et al.

    European journal of medical research 2021; (26(1)):66 doi:10.1186/s40001-021-00534-6.

    PMID: 34215328
  16. 16

    Barriers to translational research in Sjögren's syndrome with childhood onset: challenges of recognising and diagnosing an orphan rheumatic disease.

    Ciurtin C, Cho Y, Al-Obaidi M, et al.

    The Lancet. Rheumatology 2021; (3(2)):e138-e148 doi:10.1016/S2665-9913(20)30393-3.

    PMID: 38279369
  17. 17

    Predicting lymphoma development in patients with Sjögren's syndrome.

    De Vita S, Gandolfo S

    Expert review of clinical immunology 2019; (15(9)):929-938 doi:10.1080/1744666X.2019.1649596.

    PMID: 31347413
  18. 18

    Antibodies against carbamylated proteins are present in primary Sjögren's syndrome and are associated with disease severity.

    Bergum B, Koro C, Delaleu N, et al.

    Annals of the rheumatic diseases 2016; (75(8)):1494-500 doi:10.1136/annrheumdis-2015-207751.

    PMID: 26350884
  19. 19

    Pulmonary Manifestations of Primary Sjögren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management.

    Gupta S, Ferrada MA, Hasni SA

    Frontiers in immunology 2019; (10()):1327 doi:10.3389/fimmu.2019.01327.

    PMID: 31249572
  20. 20

    Increased expression of CXCL10 and CCL3 salivary gland chemokines in primary Sjögren's syndrome detected and systematically quantified using RNAscope®in situ hybridization.

    Borge H, Ringstad IB, Aqrawi LA, et al.

    Clinical and experimental immunology 2025; (219(1)) doi:10.1093/cei/uxae087.

    PMID: 39436967
  21. 21

    Involvement of CCL2 in Salivary Gland Response to Hyperosmolar Stress Related to Sjögren's Syndrome.

    Chivasso C, Parisis D, Cabrol X, et al.

    International journal of molecular sciences 2024; (25(2)) doi:10.3390/ijms25020915.

    PMID: 38255988
  22. 22

    Primary Sjögren's syndrome accompanied by pleural effusion: a case report and literature review.

    Ma D, Lu H, Qu Y, et al.

    International journal of clinical and experimental pathology 2015; (8(11)):15322-7.

    PMID: 26823888
  23. 23

    B cells in Sjögren's syndrome: from pathophysiology to therapeutic target.

    Mielle J, Tison A, Cornec D, et al.

    Rheumatology (Oxford, England) 2021; (60(6)):2545-2560 doi:10.1093/rheumatology/key332.

    PMID: 30770916
  24. 24

    2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.

    Shiboski CH, Shiboski SC, Seror R, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(1)):35-45 doi:10.1002/art.39859.

    PMID: 27785888
  25. 25

    Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome.

    Mofors J, Holmqvist M, Westermark L, et al.

    Journal of internal medicine 2019; (286(4)):458-468 doi:10.1111/joim.12941.

    PMID: 31127862
  26. 26

    Association between comorbidities and extraglandular manifestations in primary Sjögren's syndrome: a multicenter cross-sectional study.

    Zhang Y, Li M, Zhang L, et al.

    Clinical rheumatology 2020; (39(9)):2677-2688 doi:10.1007/s10067-020-04992-x.

    PMID: 32146615
  27. 27

    Imaging in Primary Sjögren's Syndrome.

    van Ginkel MS, Glaudemans AWJM, van der Vegt B, et al.

    Journal of clinical medicine 2020; (9(8)) doi:10.3390/jcm9082492.

    PMID: 32756395
  28. 28

    Primary Sjögren's syndrome.

    Bowman SJ

    Lupus 2018; (27(1_suppl)):32-35 doi:10.1177/0961203318801673.

    PMID: 30452329
  29. 29

    Increased Risk of Developing Systemic Lupus Erythematosus and Rheumatoid Arthritis in Patients with Primary Sjögren's Syndrome-A Secondary Cohort Analysis of Nationwide, Population-Based Claims Data.

    Koo M, Hsu CW, Lu MC

    Journal of clinical medicine 2023; (12(12)) doi:10.3390/jcm12124157.

    PMID: 37373849
  30. 30

    Analysis of the cell populations composing the mononuclear cell infiltrates in the labial minor salivary glands from patients with rheumatoid arthritis and sicca syndrome.

    Fragoulis GE, Fragkioudaki S, Reilly JH, et al.

    Journal of autoimmunity 2016; (73()):85-91.

    PMID: 27344240
  31. 31

    Exploring gender-related clinical and immunological profiles in Sjögren's disease in a Chinese cohort.

    Wang R, Wu J, Han Y, et al.

    Clinical rheumatology 2025; (44(10)):4081-4090 doi:10.1007/s10067-025-07616-4.

    PMID: 40833704

This page provides educational information about Sjögren's syndrome mechanisms and types. It is not a substitute for professional medical advice, diagnosis, or treatment from your rheumatologist or healthcare team.

Stay up to date

Get notified when new research about Sjögren's Syndrome is published.

No spam. Unsubscribe anytime.